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SUMMARY. A biosensor based on imaging ellipsometry (BIE)
has been developed and validated in 169 patients for
detecting five markers of hepatitis B virus (HBV) infection.
The methodology has been established to pave the way for
clinical diagnosis, including ligand screening, determination
of the sensitivity, set-up of cut-off values (CoVs) and com-
parison with other clinical methods. A matrix assay method
was established for ligand screening. The CoVs of HBV
markers were derived with the help of receiver operating
characteristic curves. Enzyme-linked immunosorbent assay
(ELISA) was the reference method. Ligands with high bio-
activity were selected and sensitivities of 1 ng/mL and 1 IU/
mL for hepatitis B surface antigen (HBsAg) and surface
antibody (anti-HBs) were obtained respectively. The CoVs of
HBsAg, anti-HBs, hepatitis B e antigen, hepatitis B e anti-
body and core antibody were as follows: 15%, 18%, 15%,
20% and 15%, respectively, which were the percentages
over the values of corresponding ligand controls. BIE can
simultaneously detect up to five markers within 1 h with
results in acceptable agreement with ELISA, and thus shows
a potential for diagnosing hepatitis B with high throughput.
Keywords: hepatitis B, imaging ellipsometry, label-free bio-
sensor, microfluidic.
INTRODUCTION
The detection of hepatitis B virus (HBV) markers is
important clinical data for the diagnosis of infection with
this virus [1]. Several methods, including enzyme-linked
immunosorbent assay (ELISA), polymerase chain reaction,
chip-based detection methods and surface plasmon reso-
nance, have been used to detect HBV markers; however,
they suffer from inherent limitations [2–5], such as
expensive equipment, specialist skills and complicated
sample preparation processes. Conventional ELISA is still
the main diagnostic test for hepatitis B [6], which has,
however, some shortcomings, such as need of tracer
labelling, indirect format of detection and length of testing
time. Thus, a rapid, simple and direct method is an urgent
need.
Compared with previous methods, biosensor based on
imaging ellipsometry (BIE) offers several advantages such as a
label-free rapid test, intuitionistic image, multiplexed analysis
and low cost. The concept of biosensor usage in diagnosis was
proposed in 1995 [7], and since then it has been successfully
applied in the biomedical field, for example, in cancer marker
detection, bacteria or virus detection, SARS antibody identi-
fication and so on [8–12]. Some initial results of hepatitis B
detection have been reported, which show that BIE is feasible
for clinical diagnosis of disease [13,14].
We report here on the BIE detection procedure for hepa-
titis B markers, including modifications and substrate,
screening and immobilization of hepatitis B ligands, sensi-
tivity, cut-off value (CoV) criteria, as well as testing of patient
sera. A systematic hepatitis B markers detection method by
means of BIE was thus established.
Abbreviations: anti-HBc, hepatitis B core antibody; anti-HBe,
hepatitis B e antibody; anti-HBs, hepatitis B surface antibody;
APTES, 3-aminopropyltriethoxy-silane; BIE, biosensor based on
imaging ellipsometry; BSA, bovine serum albumin; CoVs, cut-off
values; EDC, 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide
hydrochloride; ELISA, enzyme-linked immunosorbent assay; HBcAg,
hepatitis B core antigen; HBeAg, hepatitis B e antigen; HBsAg,
hepatitis B surface antigen; IE, imaging ellipsometry; NHS,
N-hydroxysuccinimide; PBS, phosphate-buffered saline; PBST,
phosphate-buffered saline with 1% Tween 20; ROCC, receiver
operating characteristic curves.
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Table 1 Clinical information of hepatitis B patients from Shandong Provincial Hospital
Patients
no. Age Sex
HBV markers (+is positive; ) is negative: +/)
is uncertain)
Time of sampling
Time of ELISA
detectionHBsAg HBsAb HBeAg HBeAb HBcAb
P001 47 Woman + ) + ) + 14 December 2006 14 December 2006
P002 34 Woman + ) ) + + 13 December 2006 14 December 2006
P003 22 Woman + ) + ) + 13 December 2006 14 December 2006
P004 12 Man + ) ) ) + 14 December 2006 14 December 2006
P005 50 Man + ) ) + + 14 December 2006 14 December 2006
P006 22 Woman + ) + ) ) 14 December 2006 14 December 2006
P007 27 + ) + ) + 14 December 2006 14 December 2006
P008 43 Woman + ) ) + ) 13 December 2006 14 December 2006
P009 23 Woman + ) + ) ) 14 December 2006 14 December 2006
P010 25 Woman + ) + ) ) 14 December 2006 14 December 2006
P011 50 Woman + ) ) + + 14 December 2006 14 December 2006
P012 21 Woman + ) + ) + 15 December 2006 15 December 2006
P013 38 Man + ) ) ) + 15 December 2006 15 December 2006
P014 30 Man + ) ) + + 15 December 2006 15 December 2006
P015 20 Man + ) ) + + 15 December 2006 15 December 2006
P016 48 Man + ) ) + + 15 December 2006 15 December 2006
P017 Woman + ) + ) + 15 December 2006 15 December 2006
P018 44 Woman + ) ) + + 15 December 2006 15 December 2006
P019 Woman + ) ) + + 15 December 2006 15 December 2006
P020 62 Man + ) ) + + 19 December 2006 19 December 2006
P021 56 Woman + ) ) + + 19 December 2006 19 December 2006
P022 18 Man + ) ) + + 19 December 2006 19 December 2006
P023 47 Man + ) ) + + 19 December 2006 19 December 2006
P024 44 Man + ) + ) + 19 December 2006 19 December 2006
P025 53 Man + ) ) + + 19 December 2006 19 December 2006
P026 35 Man + ) ) + + 19 December 2006 19 December 2006
P027 21 Woman + ) ) + + 19 December 2006 19 December 2006
P028 52 Man + ) ) ) + 19 December 2006 19 December 2006
P029 66 Woman + ) ) + + 19 December 2006 19 December 2006
P030 40 Man + ) ) + + 20 December 2006 20 December 2006
P031 24 Woman + ) ) ) + 20 December 2006 20 December 2006
P032 20 Woman + ) ) + + 20 December 2006 20 December 2006
P033 17 Man + ) ) ) + 20 December 2006 20 December 2006
P034 30 Woman + ) ) + + 20 December 2006 20 December 2006
P035 31 Woman + ) + ) + 20 December 2006 20 December 2006
P036 50 Woman + ) ) + + 20 December 2006 20 December 2006
P037 42 Man + ) ) + + 20 December 2006 20 December 2006
P038 34 Woman + ) + ) + 20 December 2006 20 December 2006
P039 72 Man + ) ) ) + 20 December 2006 20 December 2006
P040 32 Woman + ) ) + + 20 December 2006 20 December 2006
P041 60 Man + ) ) ) + 20 December 2006 20 December 2006
P042 32 Man + ) ) + + 21 December 2006 21 December 2006
P043 20 Woman + ) + ) + 21 December 2006 21 December 2006
P044 20 Woman + ) + ) + 21 December 2006 21 December 2006
P045 30 Man + ) ) + + 21 December 2006 21 December 2006
P046 38 Man +/) ) ) + + 21 December 2006 21 December 2006
P047 48 Man + ) + ) + 21 December 2006 21 December 2006
P048 41 Man + ) ) ) + 21 December 2006 21 December 2006
P049 19 Woman + ) + ) + 21 December 2006 21 December 2006
P050 18 Woman + ) + ) + 21 December 2006 21 December 2006
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Table 1 (Continued)
Patients
no. Age Sex
HBV markers (+is positive; ) is negative: +/)
is uncertain)
Time of sampling
Time of ELISA
detectionHBsAg HBsAb HBeAg HBeAb HBcAb
P051 32 Woman + ) ) + + 21 December 2006 21 December 2006
P052 67 Woman + ) ) + + 21 December 2006 21 December 2006
P053 38 Man + ) + ) + 22 December 2006 22 December 2006
P054 25 Woman + ) ) + + 22 December 2006 22 December 2006
P055 26 Man + ) + ) + 22 December 2006 22 December 2006
P056 58 Man + ) ) ) + 22 December 2006 22 December 2006
P057 53 Man + ) + ) + 22 December 2006 22 December 2006
P058 37 Woman + ) ) + + 22 December 2006 22 December 2006
P059 48 Man + ) ) + + 26 December 2006 26 December 2006
P060 48 Man + ) ) + + 1 January 2007 1 January 2007
60 patients were detected with ELISA kit produced by Beijing Wantai Co Ltd.
Table 2 Clinical information of hepatitis B patients from Tientsin Blood Disease Hospital
Patients
no. Age
HBV markers (ELISA OD/CoV)
Time of sampling
Time of ELISA
detectionHBsAg HBsAb HBeAg HBeAb HBcAb
1 52 0.36 33.70 0.08 0.29 0.02 21 December 2006 22 December 2006
2 40 0.41 11.10 0.14 1.73 0.30 21 December 2006 22 December 2006
3 25 7.51 0.14 0.13 0.01 0.10 21 December 2006 22 December 2006
4 53 5.71 0.08 0.08 0.73 0.02 21 December 2006 22 December 2006
5 58 0.15 30.90 0.08 0.70 0.03 21 December 2006 22 December 2006
6 61 0.10 21.70 0.13 0.13 0.03 21 December 2006 22 December 2006
8 63 0.25 3.77 0.14 0.45 0.06 21 December 2006 22 December 2006
9 46 43.80 0.08 0.08 1.52 0.01 22 December 2006 25 December 2006
10 75 0.21 41.70 0.98 0.03 0.42 23 December 2006 25 December 2006
11 54 37.50 0.11 31.90 1.69 0.01 23 December 2006 25 December 2006
12 51 42.90 0.10 0.10 0.02 0.01 23 December 2006 25 December 2006
13 30 38.60 0.98 30.70 1.01 0.01 23 December 2006 25 December 2006
14 49 42.70 0.10 0.10 2.11 0.01 23 December 2006 25 December 2006
15 64 23.70 0.24 6.87 2.87 0.03 23 December 2006 25 December 2006
16 69 38.40 0.18 0.65 1.83 0.01 23 December 2006 25 December 2006
17 40 40.90 0.12 0.11 0.17 0.01 23 December 2006 25 December 2006
19 46 48.50 0.17 37.90 1.80 0.03 24 December 2006 25 December 2006
20 69 48.90 0.21 0.05 0.60 0.01 24 December 2006 25 December 2006
21 39 45.30 0.08 0.32 1.03 0.01 24 December 2006 25 December 2006
22 60 0.11 3.47 0.19 0.69 0.05 25 December 2006 26 December 2006
23 57 24.20 0.07 0.20 0.02 0.42 25 December 2006 26 December 2006
24 19 13.60 0.06 18.90 1.01 0.02 25 December 2006 26 December 2006
25 41 25.30 0.74 19.20 1.01 0.01 26 December 2006 27 December 2006
26 47 0.11 20.20 0.24 0.55 0.99 26 December 2006 27 December 2006
27 50 0.11 34.90 0.03 0.02 0.02 26 December 2006 27 December 2006
28 56 15.50 0.01 0.20 0.51 0.01 26 December 2006 27 December 2006
29 32 0.49 26.50 0.10 0.47 0.01 26 December 2006 27 December 2006
30 64 27.50 0.23 0.16 0.02 0.02 28 December 2006 28 December 2006
31 34 35.40 0.13 0.21 0.01 0.01 28 December 2006 28 December 2006
32 54 39.70 0.21 8.35 1.24 0.02 28 December 2006 28 December 2006
33 56 0.11 2.79 0.88 0.49 0.19 28 December 2006 28 December 2006
34 50 0.11 21.90 0.08 0.02 0.02 28 December 2006 28 December 2006
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Table 2 (Continued)
Patients
no. Age
HBV markers (ELISA OD/CoV)
Time of sampling
Time of ELISA
detectionHBsAg HBsAb HBeAg HBeAb HBcAb
35 61 41.30 0.08 0.09 0.01 0.01 28 December 2006 28 December 2006
36 41 38.90 0.29 0.10 0.02 0.03 28 December 2006 29 December 2006
37 49 0.08 7.50 0.01 1.16 0.82 28 December 2006 29 December 2006
38 21 26.80 0.18 7.28 1.01 0.03 28 December 2006 29 December 2006
39 51 0.06 0.14 0.01 0.34 0.03 28 December 2006 29 December 2006
40 28 0.04 5.83 0.06 0.01 0.02 29 December 2006 29 December 2006
41 23 37.70 0.12 0.11 0.70 0.02 30 December 2006 30 December 2006
42 70 0.24 37.20 0.18 0.05 0.99 30 December 2006 30 December 2006
43 42 0.11 0.18 0.12 0.58 0.05 29 December 2006 29 December 2006
44 30 0.09 41.60 0.15 0.15 0.48 30 December 2006 30 December 2006
45 73 0.19 1.85 0.04 0.77 0.01 30 December 2006 30 December 2006
46 54 35.80 0.08 0.08 0.01 0.01 31 December 2006 31 December 2006
47 41 19.20 0.10 6.32 1.01 0.11 31 December 2006 31 December 2006
48 49 39.80 0.16 0.11 0.02 0.01 31 December 2006 31 December 2006
49 41 0.01 4.38 0.04 0.60 0.01 31 December 2006 31 December 2006
50 42 0.05 0.45 0.03 0.01 0.39 1 January 2007 1 January 2007
51 41 43.40 0.04 0.19 0.51 0.01 1 January 2007 1 January 2007
52 36 0.03 14.70 0.01 1.02 0.07 1 January 2007 1 January 2007
53 60 0.19 3.01 0.12 0.97 0.48 4 January 2007 4 January 2007
54 50 0.21 21.70 0.14 0.02 0.01 4 January 2007 4 January 2007
55 42 32.00 0.10 0.04 0.01 0.01 4 January 2007 4 January 2007
56 55 45.60 0.19 0.32 0.62 0.01 4 January 2007 4 January 2007
57 50 36.90 0.06 0.44 0.83 0.02 4 January 2007 4 January 2007
58 27 39.50 0.13 0.13 0.01 0.02 4 January 2007 4 January 2007
59 28 38.90 0.08 0.10 0.01 0.01 4 January 2007 4 January 2007
60 23 13.10 0.05 13.30 1.01 0.02 4 January 2007 4 January 2007
61 52 0.26 4.66 0.04 0.01 0.01 4 January 2007 4 January 2007
62 44 0.00 21.40 0.05 0.49 0.01 1 January 2007 1 January 2007
63 48 0.04 20.80 0.07 0.07 0.01 4 January 2007 4 January 2007
64 34 12.80 0.09 7.67 1.01 0.01 4 January 2007 4 January 2007
65 44 41.30 0.08 0.48 0.62 0.01 4 January 2007 4 January 2007
66 62 38.90 0.06 0.10 0.14 0.01 4 January 2007 4 January 2007
67 54 0.12 25.80 0.03 0.48 0.01 4 January 2007 4 January 2007
68 50 0.21 31.60 0.12 0.02 0.03 4 January 2007 4 January 2007
69 45 0.07 19.20 0.06 0.34 0.03 4 January 2007 4 January 2007
70 46 0.10 30.40 0.12 0.01 0.01 4 January 2007 4 January 2007
71 60 0.12 37.90 0.14 0.02 0.01 4 January 2007 4 January 2007
72 65 0.08 14.10 0.04 0.43 0.59 4 January 2007 4 January 2007
73 58 0.11 45.30 0.08 0.37 0.01 4 January 2007 4 January 2007
74 45 39.00 0.17 0.10 0.09 0.01 5 January 2007 5 January 2007
75 52 0.12 23.20 0.13 0.05 0.02 5 January 2007 5 January 2007
76 50 0.10 2.90 0.11 1.01 0.35 5 January 2007 5 January 2007
77 / 0.08 3.06 0.09 0.32 0.38 5 January 2007 5 January 2007
78 46 44.60 0.08 0.08 0.01 0.01 5 January 2007 5 January 2007
79 61 0.01 6.70 0.01 0.01 0.01 5 January 2007 5 January 2007
80 58 44.30 0.03 0.07 0.01 0.01 5 January 2007 5 January 2007
81 43 0.30 30.00 0.04 0.02 0.37 5 January 2007 5 January 2007
82 44 0.15 6.63 0.13 0.67 0.04 4 January 2007 4 January 2007
83 62 0.14 7.33 0.15 1.56 0.04 5 January 2007 5 January 2007
84 / 0.16 0.37 0.10 0.35 0.22 5 January 2007 5 January 2007
85 49 0.17 0.42 0.06 0.04 0.44 5 January 2007 5 January 2007
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PATIENTS AND METHODS
Study subjects, sample collection and reagents
Silicon wafers were purchased from the Luoyang Mono-
crystalline Silicon Factory (Luo, China). H2O2 (30%), H2SO4
(98%) and absolute ethanol were purchased from Beijing Bei
Hua Fine Chemicals Co Ltd (Beijing, China). 3-Amin-
opropyltriethoxy-silane (APTES, 99%, v/v), 1-(3-dimethyla-
minopropyl)-3-ethylcarbodiimide hydrochloride (EDC) and
N-hydroxysuccinimide (NHS) were purchased from ACROS
(Acros Organics, Geel, Belgium). Succinic anhydride was
purchased from Beijing Hengye Zhongyuan Chemical Co Ltd
(Beijing, China). All chemicals were of analytical grade.
Hepatitis B surface antigen (HBsAg), hepatitis B surface
antibody (anti-HBs), hepatitis B core antigen (HBcAg), hep-
atitis B core antibody (anti-HBc), hepatitis B e antigen
(HBeAg) and hepatitis B e antibody (anti-HBe) ligands were
purchased from Beijing Hotgen Biotechnology Co Ltd
(China). Anti-HBs and HBsAg national reference samples (1
and 2 ng/mL respectively) were purchased from the Na-
tional Institute for the Control of Pharmaceutical and Bio-
logical Products (Beijin, China). All sera with available
ELISA results were from Shandong Provincial Hospital and
Tientsin Blood Disease Hospital (China). ELISA kits were
purchased from Beijing Wantai Biological Pharmacy Enter-
prise Co Ltd (authorized no.: S10980089) and Shanghai
Rongsheng Biotech Co Ltd (S10950044) (China). Patient
demographic data can be found in Tables 1 and 2. Tween 20
and bovine serum albumin (BSA) were purchased from
Sigma Aldrich (St Louis, MO, USA), phosphate-buffered sal-
ine (PBS, 140 mM NaCl, 2.7 mm KCl, 10 mm Na2HPO4,
1.8 mm KH2PO4, pH 7.3), PBS with 1% Tween 20 (PBST)
and NE (0.05 mol/mL NHS, 0.2 mol/mL EDC) were prepared
Table 2 (Continued)
Patients
no. Age
HBV markers (ELISA OD/CoV)
Time of sampling
Time of ELISA
detectionHBsAg HBsAb HBeAg HBeAb HBcAb
86 40 0.06 40.60 0.11 0.02 0.14 5 January 2007 5 January 2007
87 47 0.06 32.70 0.09 1.10 0.01 8 January 2007 8 January 2007
88 36 0.09 37.30 0.10 0.05 1.78 8 January 2007 8 January 2007
89 45 49.10 0.10 0.09 0.01 0.16 8 January 2007 8 January 2007
90 70 17.90 0.15 0.11 0.06 0.03 8 January 2007 8 January 2007
92 73 51.30 0.04 0.38 0.99 0.01 8 January 2007 8 January 2007
93 79 0.14 11.30 0.06 0.11 0.14 8 January 2007 8 January 2007
94 37 0.10 27.30 0.08 1.14 0.07 8 January 2007 8 January 2007
95 54 0.41 39.50 0.13 0.01 0.01 8 January 2007 8 January 2007
96 47 0.19 32.20 0.08 0.05 0.02 8 January 2007 8 January 2007
97 55 0.25 37.60 0.10 0.56 0.05 8 January 2007 8 January 2007
98 44 0.14 20.10 0.18 0.76 0.22 8 January 2007 8 January 2007
99 30 22.40 0.30 46.80 1.01 0.02 8 January 2007 8 January 2007
100 66 33.60 0.30 0.23 0.01 0.01 8 January 2007 8 January 2007
101 46 0.13 37.10 0.25 0.38 0.02 9 January 2007 9 January 2007
102 31 18.70 0.22 37.40 1.01 0.17 9 January 2007 9 January 2007
103 34 31.20 0.13 0.20 0.45 0.01 9 January 2007 9 January 2007
104 36 0.11 0.98 0.20 0.01 0.31 9 January 2007 9 January 2007
105 59 33.60 0.09 0.18 0.88 0.06 9 January 2007 9 January 2007
106 59 30.80 0.13 0.07 0.04 0.02 9 January 2007 9 January 2007
107 43 0.25 34.50 0.07 0.44 0.01 11 January 2007 11 January 2007
108 24 35.90 0.13 20.50 0.41 0.90 11 January 2007 11 January 2007
109 65 0.25 25.40 0.21 0.60 0.22 11 January 2007 11 January 2007
110 55 64.00 0.18 0.14 0.01 0.01 11 January 2007 11 January 2007
111 33 39.00 0.25 0.02 0.01 0.01 11 January 2007 11 January 2007
112 53 0.06 1.02 0.01 0.10 0.71 10 January 2007 10 January 2007
109 patients (absence of patients no.: 7, 18, 91) were detected by ELISA kit produced by Shanghai Rongsheng Biotech CoLtd.
The absence of information was marked as /. ELISA OD/CoV of HBV markers was presented. If the value of HBeAg, HBsAb and
HBsAg detected with noncompetitive ELISA method was equal or greater than 1, the result was considered as positive. If the
value of HBcAb and HBeAb detected with competitive ELISA method was equal or lesser than 1, the result was considered as
positive.
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in deionized water (18.3 MWcm, Milli-Q plus system; Milli-
pore, Bedford, MA, USA).
BIE detection procedure and principle
First, silicon wafers were chosen as the substrate and mod-
ified by chemical reagents forming reactive groups on its
surface. Second, the modified substrate was put in a micro-
fluidic system and its surface was patterned in an array
format. Hepatitis B ligands were immobilized in different
areas. Third, sera were passed through the ligand areas and
hepatitis B markers were captured. Finally, the wafer was
taken from the microfluidic system and placed in the imag-
ing ellipsometry (IE) apparatus to analyse the results.
Imaging ellipsometry is a display technique for ultrathin
film and surface characterization [15,16]. The incident wave
of polarized light beam used as probe irradiates the substrate
and is thus modified, which makes the reflective or trans-
mission beam carry relevant sample information, for exam-
ple, protein surface concentration. When IE detects a
biomolecule layer, the value of reflection intensity is
presented in greyscale. The variation of surface concentra-
tions causes changes in the grey-scale value, which reflects
directly the molecule mass surface concentration on the
substrate. To visualize its variation across layers, the result
can also be transformed to represent the corresponding
distribution in three dimensions.
Substrate surface modification
The hydrophilic and hydrophobic modifications were the
same as in previous studies [10]. After hydrophobic modifi-
cation with APTES, a layer of densely packed amino groups
is formed on the substrate [11]. After rinsing in ethanol, the
(a) (b) (a) (b)
Fig. 2 Screening of hepatitis B ligands. (a) Screening of anti-HBs and HBsAg. Different lots of anti-HBs and HBsAg ligands
were firstly immobilized in different lines. After blocking with BSA, the first row was used as control. Different lots of HBsAg
and anti-HBs markers were detected in different rows. (b) Screening for anti-HBe and HBeAg. Anti-HBe and HBeAg ligands
were immobilized in different lines. After blocking with BSA, the first row was used as control. Different lots of HBeAg and
anti-HBe markers were detected in different rows. The italics indicate results with the largest variation in grey-scale value,
which in turn indicate that the ligands had higher bioactivity.
(a) (b) (c) (d)
Fig. 1 Microfluidic system. (a) Micro-reaction interface; (b) module for microarray; (c) schematic illustration of the micro-
fluidic system; (d) a sample of protein microarray prepared by using the microfluidic system and grey-scale image obtained
using IE. a is small cell; b is polydimethyl-siloxane film; c is organic glass with small holes; d is silicon wafer.
 2009 Blackwell Publishing Ltd
HBV marker detection with a biosensor 827
substrate is incubated in saturated succinic anhydride
solution in ethanol for 3 h. The CH2CH2COOCO of succinic
anhydride reacts with the -NH2 groups immobilized on the
substrate and generates -(CH2)3NH-CO(CH2)2-COOH. After
rinsing in ethanol, the substrate is kept in ethanol. Some
carboxyl groups are formed on the substrate, which could be
activated by NE (NHS and EDC) for ligand or protein
immobilization. In the presence of NHS, EDC can transfer
carboxyl groups to Sulfo-NHS ester, which can react with
the -NH2 groups of protein to immobilize hepatitis B ligands
covalently.
Substrate pattern and immobilization of hepatitis B ligands
Hepatitis B ligands can be patterned homogeneously and
simultaneously on the substrate in an array format by the
microfluidic system (Fig. 1). The physical size of the pat-
terned site is about 1.5 · 1 mm2. With simple microfluidic
channel junction, the microfluidic array can be used in serial
or parallel formats to analyse single or multiple samples
simultaneously [14].
Hepatitis B ligand screening with matrix assay
Hepatitis B ligands were immobilized on the substrate in an
array format, and then their bioactivities were checked
with corresponding hepatitis B markers. The process for
checking the bioactivities of anti-HBs and HBsAg ligands
was as follows. After carboxyl activation with NE (10 lL/
area), the anti-HBs and HBsAg ligands were added to the
microfluidic system (0.1 mg/mL, 10 lL/area, passing the
substrate with a flowrate of 2 lL/min for 5 min). All areas
were blocked with 10 mg/mL BSA for 30 min, and then
some areas were chosen as control to add PBST buffer. In
other areas, the corresponding pure HBsAg and anti-HBs
markers were added to interact with the corresponding
ligands immobilized on the substrate. These areas were
rinsed with deionized water between consecutive operation
steps. Then, the substrate was taken out of the microfluidic
system and its surface was rinsed with deionized water.
After blowing nitrogen, the result was read and analysed
by IE. When the same hepatitis B marker reacted with
different ligands, the results exhibited different values in the
greyscale, which indicated that the ligands had different
bioactivities.
Sensitivity
Anti-HBs was immobilized in six areas. All areas were blocked
for 30 minwith a negative serum sample (diluted 1:1 v/vwith
PBST). Sensing surface areas with anti-HBs were formed for
HBsAg marker detection. Two areas were chosen to detect
HBsAg from the national positive reference sample (1 ng/mL),
and two other areas were chosen to detect the national
HBsAg-negative reference sample as negative control. The
remaining two areas were chosen to add PBST as blank con-
trol. National positive, negative reference samples and PBST
were added (20 lL/area, 2 lL/min and 10 min respectively)
and the results were read by IE.
Serum detection and CoVs
Five hepatitis B ligands (HBsAg, HBeAg and HBcAg:
0.3 mg/mL, anti-HBs and anti-HBe: 0.1 mg/mL) were
immobilized in five rows. All areas were blocked with
negative serum reference sample for 30 min. Different lines
were chosen to detect different sera (diluted 1:15 with
PBST, 20 lL/area). CoV of each marker was analysed by
referring to receiver operating characteristic curves (ROCC)
[17], and ELISA was used as reference test criterion. Each
96-well micro-titre ELISA plate was coated with a particular
kind of hepatitis B ligand. Two wells were used as positive
and negative controls, respectively, and one well was used
as blank control. Other wells were used to detect sera. The
remaining steps were as in the instruction manual of the
ELISA kit.
(a)
(b)
Fig. 3 Sensitivity of BIE. (a) Sensitivity in detecting HBsAg.
The anti-HBs ligand was immobilized in six areas. After
blocking with the national HBsAg reference negative sam-
ple, HBsAg-positive reference samples with 1 ng/mL were
detected in area c1 and c2, and HBsAg reference negative
samples used as negative control were detected in b1 and
b2. PBST, used as blank control, was added to a1 and b1.
(b) Sensitivity in detecting anti-HBs. The anti-HBs positive
reference sample with 1 IU/mL was detected in d4 and e3,
whilst the negative samples were detected in d3 and e4.
PBST was added to f3 and f4.
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RESULTS
Hepatitis B high bioactive ligand screening
To achieve high detection rates, we selected ligands that
could interact with most of the corresponding markers. From
the analysis of grey-scale values, high bioactive anti-HBs
ligands are in lines 3 and 4, and HBsAg in line 8 (Fig. 2a).
A high bioactive anti-HBe ligand is seen in line 10, and
HBeAg in lines 12 and 14 (Fig. 2b). HBcAg ligand can also
be screened in a similar fashion.
Sensitivity
The sensitivity in detecting HBsAg reached 1 ng/mL
(Fig. 3a). The value in greyscale for the blank control
(area a1 and a2) was 63.3 ± 0.1. The value for the
negative control (area b1 and b2) was 66.7 ± 1.7, about
5% higher than that of the blank control. The value for
the positive sample (1 ng/mL, subtype ad, area c1 and c2)
was 83.4 ± 0.4, about 31.8% and 25.0% higher than the
blank and negative control respectively, which indicated
that a sample of the order of 1 ng/mL could be detected.
The sensitivity of anti-HBs was also tested (Fig. 3b). The
values for the blank control, negative control and positive
sample were 69.5 ± 1.0, 70.0 ± 0.2 and 113.9 ± 1.3
respectively, suggesting that the sensitivity might be better
than 1 IU/mL.
Clinical hepatitis B serum detection
Sixty hepatitis B patients (Table 1) with qualitative results
by ELISA were tested with BIE and an automatic BIE
operation process was established as follows: immobiliza-
(a)
(b)
Fig. 4 Comparison of HBsAg detection
by BIE (- -) and by ELISA (- D -). (a)
Original image; (b) enlarged image of
the lowest part of image (a).
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tion of ligand (10 lL, 2 lL/min, 5min), blocking of sub-
strate (40 lL, 2 lL/min, 20 min), sample detection
(20 lL, 2 lL/min, 10 min) and rinsing with deionized
water between consecutive operation steps (60 lL, 20 lL/
min, 3 min). Five markers from seven patients could be
detected on a single substrate in 1 h or less. With this
operation process, 109 samples (Table 2) were detected.
The HBsAg detection results using BIE were compared
with those of ELISA, as shown in Fig. 4, and Table 3.
Regression analysis showed that the results were in quite
good agreement between the two methods (r = 0.67 >
r0.01 = 0.247). The degree of agreement between BIE and
ELISA in detecting HBsAg, anti-HBs, HBeAg, anti-HBe and
anti-HBc was 90.3%, 90.2%, 71.3%, 90.6% and 94.4%
respectively.
Cut-off values for HBsAg and anti-HBs were derived
from ROCC (Fig. 5). The CoV was determined by the value
in greyscale above the corresponding ligand control. When
both the positive likelihood ratio and Youdens index
reached their maxima, the corresponding variation in
grey-scale value was taken as the best CoV point [17], as
shown in Fig. 5. If there were two maxima of the same
value, the bigger variation in grey-scale value was
taken as the best CoV point to avoid false positives. The
values of CoV for HBsAg, anti-HBs, HBeAg, anti-HBe and
anti-HBc were 15%, 18%, 15%, 20% and 15%
respectively.
DISCUSSION
Ligand screening has applications in clinical diagnosis of
hepatitis B and is also helpful for developing BIE. At present,
various kinds of ligands have been produced by various
factories, but their bioactivity has large diversity even
among different lots of the same products. Most ligands are
suited to conventional methods only, and few ligands match
BIE. When the same marker is detected, different ligands on
the substrate exhibit different bioactivity. Polyclonal anti-
body ligands cannot guarantee full sensitivity [18], and
artificial ligands cannot exhibit entirely natural bioactivity.
If a ligand has high bioactivity, it is possible to achieve
higher sensitivity and efficiency, which can be verified by the
HBsAg Elecsys assay [19]. If ligands were not screened,
marker detection would have high false positive rates and
low sensitivity, and thus ligand screenings are necessary for
successful BIE.
Cut-off values and sensitivity are important for hepatitis B
marker detection. CoVs can help us to distinguish strong
positive, near cut-off and negative samples. ELISA kits have
different CoVs for different markers and BIE also gives dif-
ferent CoVs, which are helpful in distinguishing each marker
accurately. ELISA has detection limits as low as 1 ng/mL of
HBsAg [20] and 10 mIU/mL of anti-HBs [21]. However, it
must be noted that sensitivity for HBsAg detection has not
been evidently improved in the last 10 years, and the most
Table 3 HBsAg detection results of BIE and ELISA. Data of BIE were the variation of value in greyscale above the corre-
sponding ligand control. Data of ELISA were the variation of OD above the corresponding ligand control
BIE ELISA BIE ELISA BIE ELISA BIE ELISA BIE ELISA
0.07 0.36 0.10 25.3 0.22 19.2 0.16 0.07 0.38 51.3
0.11 0.41 0.17 0.11 0.22 39.8 0.08 0.1 0.03 0.14
0.16 7.51 0.04 0.11 0.05 0.01 0.08 0.12 0 0.1
0.13 5.71 0.15 15.5 0.22 0.05 0.09 0.08 0.08 0.41
0.06 0.15 0.19 0.49 0.12 43.4 0.03 0.11 0.03 0.19
0.06 0.1 0.23 27.5 0.08 0.03 0.30 39 0.06 0.25
0.07 0.25 0.16 35.4 0.02 0.19 0.04 0.12 0.29 0.14
0.40 43.8 0.27 39.7 0 0.21 0.07 0.1 0.24 22.4
0.11 0.21 0.13 0.11 0.12 32 0.05 0.08 0.37 33.6
0.33 37.5 0.05 0.11 0.08 45.6 0.34 44.6 0.04 0.13
0.24 42.9 0.37 41.3 0.16 36.9 0.05 0.01 0 18.7
0.30 38.6 0.18 38.9 0.39 39.5 0.46 44.3 0.34 31.2
0.24 42.7 0.16 0.08 0.14 38.9 0.08 0.3 0.07 0.11
0.19 23.7 0.27 26.8 0.19 13.1 0.08 0.15 0.30 33.6
0.17 38.4 0.18 0.06 0.17 0.26 0.07 0.14 0.28 30.8
0.28 40.9 0.18 0.04 0.04 0 0.08 0.16 0.06 0.25
0.24 48.5 0.20 37.7 0.05 0.04 0.08 0.17 0 35.9
0.17 48.9 0.21 0.24 0.20 12.8 0.08 0.06 0.02 0.25
0.31 45.3 0.03 0.11 0.34 41.3 0.07 0.06 0.04 64
0.15 0.11 0.09 0.09 0.27 38.9 0 0.09 0.25 39
0.09 24.2 0.16 0.19 0.09 0.12 0.34 49.1 0 0.06
0.16 13.6 0.30 35.8 0.08 0.21 0.09 17.9
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sensitive detection gained market approval in 1995 [22,23].
The HBsAg detection limit of newly licensed tests in Europe
is now under 0.15 ng/mL (enzyme-linked fluorescent
immunoassay) [24]. Compared with the label methods, al-
though the sensitivity of BIE has already reached clinical
standard, it is still at a low level, and further improvements
in sensitivity are still needed.
Biosensor based on imaging ellipsometry is able to realize
multiplexed analysis, a simplified process and short test time.
It can detect five markers of several patients simultaneously
in about 1 h and higher throughput is possible with an
improved setup, whereas ELISA can detect only one marker
on each plate over a longer test time (ligand immobilizing
and assaying lasts 1–2 days). BIE allows us to test crude
samples in a label-free method, with a simple process. Fur-
thermore, contaminating spots can also be easily discerned
with the help of visual BIE images to avoid false signals.
Thus, BIE has some merits over ELISA.
In conclusion, BIE has potential in the detection of hepa-
titis B markers with an acceptable accuracy.
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